Know Cancer

or
forgot password

Initiation of Androgen Deprivation Therapy for the Treatment of Prostate Cancer Using Degarelix Acetate Followed by Leuprolide Acetate


N/A
18 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

Initiation of Androgen Deprivation Therapy for the Treatment of Prostate Cancer Using Degarelix Acetate Followed by Leuprolide Acetate


Inclusion Criteria:



- 18 years or older

- Histologically confirmed adenocarcinoma of the prostate

- Androgen deprivation therapy is indicated

Exclusion Criteria:

- Baseline screening serum testosterone <150ng/dL

- Eastern Cooperative Oncology Group (ECOG) score > 2

- Diagnosed spinal or brain metastases

- Hormonal manipulation within previous 6 months

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Testosterone measurement

Outcome Time Frame:

11 times over 6 months

Safety Issue:

No

Principal Investigator

Robert Given, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Urology of Virginia

Authority:

United States: Institutional Review Board

Study ID:

UVA002

NCT ID:

NCT01344564

Start Date:

April 2011

Completion Date:

August 2012

Related Keywords:

  • Prostate Cancer
  • Prostate cancer
  • Hormone therapy
  • Testosterone measures
  • Prostatic Neoplasms

Name

Location

Urology of VirginiaNewport News, Virginia  23606